Kymera Therapeutics (KYMR) Insider Booth Sells $10M of Stock

Insider Buying and Selling at Kymera Therapeutics, Inc.

Bruce Booth sold 115,056 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 18, 2026, for about $10.5 million. The shares were sold at an average price of $91.01 each, part of a planned transaction. This sale adds to Booth's recent activity, where he has sold shares valued at over $65 million in the past week alone.

Recent Insider Activity

This sale is part of a series of planned transactions by Booth. Just days prior, he sold 1,408 shares on June 23, 2026, for approximately $140,772, and 278,128 shares on June 22, 2026, valued at about $27.6 million. On June 25, 2026, he sold 548,321 shares for roughly $65.1 million. These transactions indicate a pattern of Booth managing his holdings in the company as it continues its clinical trials and development efforts.

Stock Performance Context

Kymera Therapeutics shares were trading at $99.45 on June 18, 2026. The stock has seen a 52-week low of $50.35 and a high of $130.05, reflecting significant volatility. This recent sale comes as the stock was trading below its 200-day moving average of $91.61, which may raise questions about the timing of Booth's sales.

Analysts Set New Price Targets

On October 9, 2026, Raymond James initiated coverage on Kymera Therapeutics with an outperform rating and a price target of $140. Citigroup maintained its buy rating on October 5, 2026, raising its target to $150. Other firms like Stifel and B of A Securities also hold buy ratings, reflecting strong analyst support for the company. The consensus recommendation remains a strong buy with a mean target price of $138.64 based on 22 analyst opinions.

What Kymera Therapeutics, Inc. Does

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing small molecule therapeutics that degrade disease-causing proteins, targeting conditions like atopic dermatitis and various autoimmune diseases. The company is currently engaged in several clinical trials, which are crucial for its growth and valuation.

What to Watch at Kymera Therapeutics, Inc.

The next earnings report for Kymera Therapeutics is scheduled for November 3, 2026. Investors will be keen to see how the company progresses in its clinical trials and how these developments affect its financial standing. As a reminder, the insider transactions reported reflect holdings as of the date of the trades and may not fully represent current positions.